We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
India’s Ministry of Health and Family Welfare has begun publishing data about compensation paid in clinical trial-related deaths, with the first wave of data covering 2010 into 2013. Read More
U.S. Food and Drug Administration Commissioner Margaret Hamburg said her 10-day trip to India succeeded in syncing U.S.-India views on quality of medical products. Read More
It appears highly likely that the European Parliament won’t finalize the proposed medical device and IVD regulations before May elections, a lawyer familiar with the legislation says. Read More
China’s State Council last month approved the Medical Device Regulations (Amendment Bill), framework, paving the way for broad changes in device classification, adverse event reporting and monitoring of quality in device manufacturing. Read More
An FDA action plan on subgroup analysis, currently in the works, could make device trials excessively large and expensive by imposing unnecessary requirements, AdvaMed warns. Read More
Four patients died after switching to a new form of controller for Thoratec’s HeartMate II Left Ventricular Assist System, the company revealed in a Tuesday recall announcement, adding the deaths did not involve a product malfunction. Read More
The current kerfuffle around online direct-to-consumer genetic testing service 23andMe.com came out of “a perfect storm” that led to the widespread marketing of such tests, experts say. Read More
The Centers for Medicare & Medicaid Services should ensure that patients receiving care through the new Accountable Care Organizations are not denied innovative treatments due to cost, AdvaMed says in comments to CMS Administrator Marilyn Tavenner. Read More
Devicemakers will be able to distribute a wider range of clinical practice guidelines and medical textbooks to physicians under loosened FDA restrictions for off-label promotion. Read More
St. Jude’s Sylmar, Calif., plant, which makes most of its CRM products, should soon emerge from an FDA warning letter, CEO Dan Starks said on the company’s earnings call last month. Read More